Bayer HealthCare launches cannabinoid treatment for Multiple Sclerosis
Acteon is working with Bayer HealthCare to support the UK launch of Sativex, Bayer's novel cannabinoid add-on treatment for spasticity in multiple sclerosis.
The Sativex team was faced with the task of developing a fully operational launch campaign within 18 weeks, a process which would normally take 18 months. The introduction of a new brand to the portfolio required a new way of working both internally and externally. And the nature of Sativex brought its own specific hurdles which needed to be addressed.
For the training materials the content, tone and flexibility were paramount in ensuring a deep, continual understanding of both the disease area and Sativex, enabling the field force to maximise the full potential in gaining patient access.
To successfully meet this challenge, Acteon has created comprehensive distance and classroom learning materials and assessments to ensure that the field force understand and can communicate how Sativex will bring real benefits to people suffering from unrelieved spasticity in MS. These have been very well received by the Bayer training team.